Ondansetron Wockhardt Uk (Ondansetron Hydrochloride Dihydrate)

Ondansetron acts on the serotonergic pathway to control nausea and vomiting in several clinical settings.

• Chemotherapy‑induced nausea and vomiting: reduces frequency and severity of nausea and vomiting in patients receiving emetogenic chemotherapy.
• Radiation‑induced nausea and vomiting: mitigates nausea and vomiting caused by radiotherapy to the abdomen or pelvis.
• Postoperative nausea and vomiting: prevents and treats nausea and vomiting following surgical procedures.

• Ondansetron selectively blocks 5‑HT3 receptors located on vagal nerve terminals and in the chemoreceptor trigger zone of the brain. By inhibiting serotonin binding at these sites, it interrupts the neural signaling cascade that initiates the emetic response, thereby reducing nausea and vomiting triggered by chemotherapy, radiation, or surgery.

Common Side Effects

• Headache: mild to moderate pain often resolves without intervention.
• Constipation: reduced bowel movements that may require dietary adjustment.
• Diarrhoea: loose stools that are usually self‑limiting.
• Dizziness: transient sensation of light‑headedness.

Serious or Rare Side Effects

• QT prolongation: may predispose to cardiac arrhythmias, especially in patients with existing risk factors.
• Severe allergic reaction (anaphylaxis): rapid onset of rash, swelling, and breathing difficulty.
• Serotonin syndrome: rare but potentially life‑threatening condition when combined with other serotonergic agents.

Before initiating therapy, consider the following precautions:

• Cardiac assessment: evaluate baseline ECG in patients with known heart disease.
• QT interval monitoring: avoid concomitant use of other QT‑prolonging drugs.
• Hepatic impairment: use with caution in patients with severe liver dysfunction.
• Hypersensitivity: discontinue if signs of allergic reaction appear.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Ondansetron may interact with several medicines; awareness of the interaction level helps guide safe use.

Major Interactions (Avoid)

• Apomorphine: co‑administration can cause severe hypotension.
• Other QT‑prolonging agents (e.g., quinidine, amiodarone): increase risk of cardiac arrhythmias.
• Serotonergic drugs (e.g., SSRIs, MAO inhibitors): raise the potential for serotonin syndrome.

Moderate Interactions (Monitor Closely)

• Carbamazepine: induces metabolism, potentially reducing ondansetron efficacy.
• Rifampin: enhances hepatic clearance, may lower plasma concentrations.
• Aprepitant: may increase ondansetron levels, requiring dose adjustment.